Clinical Trials Logo

Seroconversion clinical trials

View clinical trials related to Seroconversion.

Filter by:
  • None
  • Page 1

NCT ID: NCT04756271 Completed - Clinical trials for Vaccine Adverse Reaction

Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection

Start date: February 11, 2021
Phase: Phase 3
Study type: Interventional

After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports regarding the application of vaccine are still limited and deficient.

NCT ID: NCT04563650 Active, not recruiting - Covid19 Clinical Trials

COVID-19 Serology and Immunosenescence

SERO-CoV-OLD
Start date: September 18, 2020
Phase: N/A
Study type: Interventional

This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors. This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.